Monument Therapeutics Announces Grant of US Patent for MT1988, a Novel Treatment for Cognitive Impairment Associated with Schizophrenia
Manchester, UK, April 30, 2026 Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. patent 12,594,270 covering MT1988, a fixed-dose combination being developed for the treatment of cognitive impairment associated with schizophrenia. The patent, […]
Monument Therapeutics Announces First Patient Dosed in Clinical Trial of MT1988 in Patients at Clinical High Risk for Psychosis
Manchester, UK, March 10, 2026 Monument Therapeutics, a stratified medicine company, today announced that the first patient has been dosed in its proof-of-principle clinical trial with MT1988 in patients at clinical high risk (CHR) for psychosis. The study is being conducted in collaboration with the Foundation for the National Institutes of Health (FNIH) as part […]
Monument Therapeutics Announces Partnership with Foundation for the National Institutes of Health for Clinical Trial of MT1988, a Novel Treatment for Schizophrenia
Manchester, UK, 19 August 2025 Monument Therapeutics, a stratified medicine company, today announced a partnership with the Foundation for the National Institutes of Health (FNIH) to evaluate MT1988, a novel treatment in development for cognitive impairment associated with schizophrenia, in a proof of principle clinical trial. Schizophrenia is a severe mental health disorder and ranks […]
Monument Therapeutics Reports Positive Phase I Results for Novel Cognitive Impairment Associated with Schizophrenia Treatment
Manchester, UK, 23 June 2025 Monument Therapeutics, a precision neuroscience company, today announced positive topline results from its Phase I clinical trial evaluating MT1988, a novel treatment targeting cognitive impairment associated with schizophrenia (CIAS). MT1988 is a fixed-dose combination of two well-established small molecules that act on nicotinic receptors, designed to optimise safety and efficacy. […]
Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board
Manchester, UK, 17 April 2025 Monument Therapeutics, a precision neuroscience company focused on the development of innovative treatments for serious central nervous system disorders (CNS), today announced two key leadership appointments. Robert S. Radie (Bob) has been appointed Non Executive Chair of the Board, effective immediately, and Dr Heather Preston has joined the company’s advisory […]
Monument Therapeutics Secures £850k to Advance Breakthrough Schizophrenia Treatment
Manchester, UK, 25 February 2025 Monument Therapeutics, an innovative neuroscience company applying digital biomarkers to psychiatric drug development, has secured £850k in further funding led by ACF Investors, with participation from Wren Capital, o2h Ventures, and angel investors. The investment will be used to fund its schizophrenia programme and drive the next stage of growth […]
Monument Therapeutics Announces Grant of Chinese Patent in Support of its MT1988 Cognitive Impairment Associated with Schizophrenia Program
Manchester, UK, 21 January 2025 Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the China National Intellectual Property Administration (“CNIPA”) has granted Chinese patent ZL202080036867.6, in support of its MT1988 program for cognitive impairment associated with schizophrenia (CIAS). The patent, […]
Monument Therapeutics Announces Grant of Japanese Patent in Support of its MT1988 Cognitive Impairment Associated with Schizophrenia Program
Manchester, UK, 14 January 2025 Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the Japan Patent Office (“JPO”) has granted Japanese patent 7570345, in support of its MT1988 program for cognitive impairment associated with schizophrenia (CIAS). The patent, which is expected […]
Post-Covid-19 cognitive impairment: a new target for drug development?
Dr Paula Moran, Dr Kiri Granger, Dr J Mark Treherne, and Dr Jenny Barnett explore the effects of long Covid-19 symptoms and what the opportunities are for drug developers working to treat post-Covid-19 cognitive impairment.
Post-Covid-19 cognitive impairment: a new target for drug development?
Dr Paula Moran, Dr Kiri Granger, Dr J Mark Treherne, and Dr Jenny Barnett explore the effects of long Covid-19 symptoms and what the opportunities are for drug developers working to treat post-Covid-19 cognitive impairment. Click here to read the article online Alternatively, click here to download the PDF
The rise of digital biomarkers in neuroscience drug development
Will an expansion in the use of effective digital biomarkers help improve the productivity of drug development in neuroscience? Ask Dr J. Mark Treherne, Dr Jenny Barnett and Dr Paula Moran. Click here to download the article
We are attending the BIO Conference: join us at two exciting sessions
We will be participating at the upcoming Biotechnology Innovation Organization conference taking place in San Diego, California, June 13-16. Members of our team will be speaking at two incredibly exciting sessions: Tackling Post-Covid Cognitive Impairment Wednesday, June 15th, 4:15pm – 5:15pm PDT https://www.bio.org/events/bio-international-convention/sessions/916081 Speaker: Dr Kiri Granger, Monument Tx, CSO Widespread evidence shows that cognitive problems are the […]
Our CEO Jennifer Barnett is featured in The Guardian in an important article discussing the critical impact of postoperative cognitive dysfunction (POCD)
Proud that our CEO Jennifer Barnett is featured in The Guardian in an important article discussing the critical impact of postoperative cognitive dysfunction (#POCD). As the article notes, estimates suggest that the overall incidence of POCD in older patients can be as high as 50-80% at discharge, 20-50% at six weeks and 10-30% at six months post-surgery. New therapies are […]
Our CSO Dr Kiri Granger is listed as one of In Vivo’s 2022 ‘Rising Leaders’!
We are very proud that our fantastic CSO Dr Kiri Granger has been listed as one of In Vivo‘s 2022 ‘Rising Leaders’! The third annual listing of In Vivo’s ‘Rising Leaders’ includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care. Included for 2022 are investors, CEOs of small and mid-sized […]
Our CEO Jennifer Barnett will be speaking at the Neuroimmunology Drug Development Summit, taking place next week in Boston, MA
Our CEO Jennifer Barnett will be speaking at the Neuroimmunology Drug Development Summit, taking place next week in Boston, MA. Don’t miss her in-person talk: Using Digital Biomarkers to Apply a Stratified Approach to Neuroinflammation When: April 19th, 9AM EST Synopsis Applying digital biomarkers, in combination with standard inflammatory markers, to aid identification of people at high […]
New Interview in Scrip
New interview in Scrip! Read more about our novel approach to CNS drug development and our focus on repurposing existing drugs with the aid of digital biomarkers. Read the interview here. For further information, contact: Jenny Barnett, CEO E: jbarnett@monumenttx.com Media: Richard Hayhurst/Janet Joy E: Richard@rhapr.eu or jan@rhapr.eu Tel: +44 7711 821527 Notes to Editors: […]